Ono has received exclusive global rights to develop and commercialise the antibody drug candidates resulting from the collaboration. Credit: Quality Stock Arts/Shutterstock.com.

Ono Pharmaceutical has signed a collaboration agreement with EVQLV to utilise its artificial intelligence (AI)-powered antibody design engine to develop new antibody drugs.

The partnership aims to leverage EVQLV’s advanced technology to generate therapeutic antibody designs against multiple targets selected by Ono.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

These designs will serve as a foundation for Ono to create potential antibodies and advance their development and commercialisation.

Ono discovery and research senior executive officer and executive director Dr Toichi Takino stated: “We are very pleased to collaborate with EVQLV having its proprietary AI-powered antibody design engine.

“We expect that the EVQLV’s AI technology will enable us to create novel antibody candidates against multiple targets more promptly and effectively.”

Ono has committed to providing research funding to EVQLV and making research milestone payments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ono will also secure exclusive global rights to develop and commercialise the antibody drug candidates resulting from this collaboration.

EVQLV’s platform is known for its integration of evolution, structure and protein language models, which enables the generation of target-specific antibody sequences.

The technology is designed to maintain the structural and functional integrity of antibodies, thus streamlining the process from recombinant antibody expression to functional testing.

EVQLV CEO and co-founder Andrew Satz stated: “At EVQLV, our mission is to make AI easily accessible to researchers in order to positively impact the odds of success in drug discovery. We are honoured to be working alongside the scientific and drug development experts at Ono, who have the ability to leverage our AI-designed antibodies and deliver breakthrough options for patients in need.”